Timothy A. Vortherms
AbbVie (United States)(US)
Publications by Year
Research Areas
Ion channel regulation and function, Receptor Mechanisms and Signaling, Pain Mechanisms and Treatments, Cystic Fibrosis Research Advances, Neuropeptides and Animal Physiology
Most-Cited Works
- → Nigrostriatal Dopaminergic Deficits and Hypokinesia Caused by Inactivation of the Familial Parkinsonism-Linked Gene DJ-1(2005)543 cited
- → Salvinorin A: From Natural Product to Human Therapeutics(2006)91 cited
- → Identification of the Molecular Mechanisms by Which the Diterpenoid Salvinorin A Binds to κ-Opioid Receptors(2005)91 cited
- → Discovery of 4-[(2 R ,4 R )-4-({[1-(2,2-Difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-7-(difluoromethoxy)-3,4-dihydro-2 H -chromen-2-yl]benzoic Acid (ABBV/GLPG-2222), a Potent Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Corrector for the Treatment of Cystic Fibrosis(2017)76 cited
- → Structure−Activity Studies on a Series of a 2-Aminopyrimidine-Containing Histamine H4Receptor Ligands(2008)58 cited
- → cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), A New Histamine H4R Antagonist that Blocks Pain Responses against Carrageenan-Induced Hyperalgesia(2008)48 cited
- → Differential Helical Orientations among Related G Protein-coupled Receptors Provide a Novel Mechanism for Selectivity(2006)40 cited
- → Sensitization of Neuronal A2A Adenosine Receptors after Persistent D2 Dopamine Receptor Activation(2004)39 cited
- → Discovery of ABBV/GLPG-3221, a Potent Corrector of CFTR for the Treatment of Cystic Fibrosis(2019)37 cited
- → A-1048400 is a novel, orally active, state-dependent neuronal calcium channel blocker that produces dose-dependent antinociception without altering hemodynamic function in rats(2011)34 cited